Nexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS, and what generic alternatives to NEXUS drugs are available?
NEXUS has twenty-one approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
There are ten patent family members on NEXUS drugs in nine countries and eighty-eight supplementary protection certificates in nine countries.
Summary for Nexus
| International Patents: | 10 |
| US Patents: | 5 |
| Tradenames: | 23 |
| Ingredients: | 20 |
| NDAs: | 21 |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | BUSULFAN | busulfan | INJECTABLE;INJECTION | 207794-001 | Jan 14, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Nexus | TRANEXAMIC ACID | tranexamic acid | SOLUTION;INTRAVENOUS | 216877-001 | Apr 16, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 213947-002 | Jul 24, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | POTASSIUM CHLORIDE 40MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-005 | Mar 18, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 213532-002 | Jul 6, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | POTASSIUM CHLORIDE 10MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-001 | Mar 18, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 215290-001 | Feb 14, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3140043 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2020232424 | ⤷ Sign Up |
| Japan | 2022532657 | ⤷ Sign Up |
| Israel | 288044 | ⤷ Sign Up |
| Australia | 2020276619 | ⤷ Sign Up |
| Mexico | 2021013888 | ⤷ Sign Up |
| South Korea | 20220009985 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1175904 | 2007C/048 | Belgium | ⤷ Sign Up | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
| 0788511 | SPC/GB08/036 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| 0478363 | 48/1999 | Austria | ⤷ Sign Up | PRODUCT NAME: TIROFIBAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-23140 UND 1-23141 19990714; FIRST REGISTRATION: LI IKS-NR 54761 19980528 |
| 1856135 | 2020/017 | Ireland | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
| 0478363 | 2000C/002 | Belgium | ⤷ Sign Up | PRODUCT NAME: TIROFIBANUM HYDROCHLORIDUM (EQ. TIROFIBAN); NAT. REGISTRATION NO/DATE: 922 IS 191 F 12 19990906; FIRST REGISTRATION: CH 54761 19980528 |
| 2822954 | 1890030-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
| 1948158 | 1690020-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
